Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

Mise à jour : Il y a 4 ans
Référence : NCT00097838

Femme et Homme

Extrait

The purpose of this study is to evaluate the safety of and immune response to an alphavirus replicon, HIV-1 subtype C gag vaccine, AVX101, in HIV uninfected adults in the United States, South Africa, and Botswana.


Critère d'inclusion

  • HIV Infections

Liens